TANDIM: Treating Anxiety and Depression in Irritable Bowel Syndrome (IBS) using diet: A proof-of-concept study

Not Applicable

Completed

• Conditions: Irritable Bowel Syndrome; Anxiety; Depression; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon; Mental Health - Anxiety; Mental Health - Depression

• Registration Number: ACTRN12620001362987
• Lead Sponsor: Deakin University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-12-17
• Study Completion: 2022-07-27
• Last Update Posted: 4 December 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 59

Inclusion Criteria

Inclusion criteria
• Aged 18-65 years
• IBS diagnosis (Rome IV criteria) of any IBS subtype (diarrhea-predominant, constipation-predominant, mixed, un-subtyped)
• Hospital anxiety and depression score (HADS) subscale score of 8-14, indicating mild or moderately severe anxiety or depressive symptoms
•Access to computer and internet access

Exclusion Criteria

• Known or suspected major medical conditions
• Females who report to be pregnant or lactating
• Unable to follow Mediterranean diet study recommendations (e.g. veganism, lacto-ovo vegetarians, inability to follow for sociocultural or religious reasons)
• Co-existing eating disorder or highly disordered eating
• Underweight (BMI <18.5 kg/m2) or obesity (>40 kg/m2)
• Change in IBS or anxiety/depression medication or exposure to pre- or probiotic supplements in the last month or antibiotics or bowel preparation for investigative procedures within the past three months

Study & Design

• Study Type: Interventional
• Study Design: Not specified